Evidence map›Paper›PMID 32939324›Full record

ReviewOncoimmunology2020

Immune responses during COVID-19 infection.

Cléa Melenotte, Aymeric Silvin, Anne-Gaëlle Goubet, Imran Lahmar, Agathe Dubuisson, Alimuddin Zumla, Didier Raoult, Mansouria Merad, Bertrand Gachot, Clémence Hénon and 12 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncoimmunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Host factors of SARS-CoV-2 in infection, pathogenesis, and long-term effects.Frontiers in cellular and infection microbiology · 2024
    Review
  17. Observational
  18. Observational
  19. Article
  20. Review

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Cléa MelenotteImmunology, Gustave Roussy, Villejuif, France.
Aymeric SilvinImmunology, Gustave Roussy, Villejuif, France.
Anne-Gaëlle GoubetImmunology, Gustave Roussy, Villejuif, France.
Imran LahmarImmunology, Gustave Roussy, Villejuif, France.
Agathe DubuissonImmunology, Gustave Roussy, Villejuif, France.
Alimuddin ZumlaDepartment of Infection, Division of Infection and Immunity, University College London, National Institute for Health Research Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK.
Didier RaoultGustave Roussy, Université Paris-Saclay, Villejuif, France.
Mansouria MeradService de Urgences et de Permanence des Soins, Gustave Roussy Cancer Campus Grand Paris, Villejuif, France.
Bertrand GachotImmunology, Gustave Roussy, Villejuif, France.
Clémence HénonImmunology, Gustave Roussy, Villejuif, France.
Eric SolaryImmunology, Gustave Roussy, Villejuif, France.
Michaela FontenayINSERM U1016, Centre National Recherche Scientifique (CNRS) UMR8104, Institut Cochin, Université de Paris, Paris, France.
Fabrice AndréImmunology, Gustave Roussy, Villejuif, France.
Markus MaeurerImmunosurgery, Immunotherapy Unit, Champalimaud Centre for the Unknown, Lisbon, Portugal.
Giuseppe IppolitoDipartimento di Epidemiologia Ricerca Pre-Clinica e Diagnostica Avanzata, National Institute for Infectious Diseases "Lazzaro Spallanzani" I.R.C.C.S., Rome, Italy.
Mauro PiacentiniDepartment of Biology, University of Rome "Tor Vergata", Rome, Italy.ORCID 0000-0003-2919-1296
Fu-Sheng WangNational Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Florent GinhouxSingapore Immunology Network, Agency for Science, Technology and Research, Singapore.
Aurélien MarabelleInfectious Diseases, Aix-Marseille Université, IRD, APHM, MEPHI, Marseille, France.
Guido KroemerCentre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France.ORCID 0000-0002-9334-4405
Lisa DerosaImmunology, Gustave Roussy, Villejuif, France.
Laurence ZitvogelImmunology, Gustave Roussy, Villejuif, France.ORCID 0000-0003-1596-0998

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past 16 years, three coronaviruses (CoVs), severe acute respiratory syndrome CoV (SARS-CoV) in 2002, Middle East respiratory syndrome CoV (MERS-CoV) in 2012 and 2015, and SARS-CoV-2 in 2020, have been causing severe and fatal human epidemics. The unpredictability of coronavirus disease-19 (COVID-19) poses a major burden on health care and economic systems across the world. This is caused by the paucity of in-depth knowledge of the risk factors for severe COVID-19, insufficient diagnostic tools for the detection of SARS-CoV-2, as well as the absence of specific and effective drug treatments. While protective humoral and cellular immune responses are usually mounted against these

Indexed as

COVID-19Host Microbial InteractionsHumansImmunity, CellularImmunity, HumoralMiddle East Respiratory Syndrome CoronavirusProtective FactorsRisk FactorsSARS-CoV-2Severe acute respiratory syndrome-related coronavirusSeverity of Illness IndexcellularCoronavirusCovid-19humoralimmune responseimmunitySars-CoV-2

Identifiers

PMID32939324
PMCPMC7480812

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.